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Abstract 
The resection of regional lymph nodes in the basin of a primary tumor is of paramount importance 
in surgical oncology. Although sentinel lymph node mapping is now the standard of care in breast 
cancer and melanoma, over 20% of patients require a completion lymphadenectomy. Yet, there is 
currently no technology available that can image all lymph nodes in the body in real time, or assess 
both the sentinel node and all nodes simultaneously. In this study, we report an optical fluores-
cence technology that is capable of simultaneous mapping of pan lymph nodes (PLNs) and sentinel 
lymph nodes (SLNs) in the same subject. We developed near-infrared fluorophores, which have 
fluorescence emission maxima either at 700 nm or at 800 nm. One was injected intravenously for 
identification of all regional lymph nodes in a basin, and the other was injected locally for identi-
fication of the SLN. Using the dual-channel FLARE intraoperative imaging system, we could identify 
and resect all PLNs and SLNs simultaneously. The technology we describe enables simultaneous, 
real-time visualization of both PLNs and SLNs in the same subject. 
Key words: Near-infrared fluorescence, pan lymph node mapping, completion lymphadenectomy, 
sentinel lymph node mapping, image-guided surgery, cervical cancer. 
Introduction 
The sentinel lymph node (SLN) is the first lymph 
node (LN) receiving lymphatic drainage from a pri-
mary tumor [1]. SLN biopsy is essential for staging 
many cancers and avoiding unnecessary LN dissec-
tion, which may cause adverse effects such as 
lymphedema. Currently, SLN biopsy is the accepted 
standard of care for breast cancer and melanoma [2]. 
Although SLN biopsy studies have been attempted 
for colorectal cancer, gastric cancer, esophageal can-
cer, head and neck cancer, thyroid cancer, non-small 
cell lung cancer, and gynecologic cancer, the im-
portance of SLN biopsy for these cancers remains un-
clear [3-9].  
Regardless of SLN status, the prognosis of al-
most all solid tumors is dependent on LN involve-
ment, and even in the case of a positive SLN biopsy, 
completion lymphadenectomy is required in 15-40% 
of cases [10-13]. Despite these facts, there is currently 
no technology available to the surgeon to identify all 
LNs within a basin quickly and with high sensitivity. 
Previous reports demonstrated that the use of invisi-
ble near-infrared (NIR) light (700 - 900 nm) has several 
advantages for SLN biopsy, including relatively high 
penetration (up to 5-8 mm) into living tissue [14, 15]. 
When compared to blue dyes, invisible NIR light has a 
relatively high signal-to-background ratio (SBR) due 
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to low absorption, scattering, and tissue autofluores-
cence [16]. NIR light is also non-ionizing. Because of 
these advantages, many recent studies have used NIR 
fluorescence for SLN biopsy [17-24], reviewed in [25]. 
PLN mapping, however, has not yet been widely in-
vestigated. Josephson et al. employed Cy5.5-grafted 
polymers (PGC) to demonstrate NIR imaging of 
PLNs; however, nonspecific background was so high 
in major organs including liver, spleen, and lungs that 
the entire viscera had to be removed to identify the 
LNs after intravenous injection [26]. 
In this study, we engineered novel small mole-
cule-based polymethine cyanine fluorophores to have 
fluorescence emission maxima in two distinct ranges; 
one NIR color for visualization of PLNs and the other 
for mapping SLN in the same subject. These 
LN-targeted NIR fluorophores were injected into 
small and large animal models, and their targeting 
efficiency in PLN and SLN was evaluated using the 
dual-channel FLARE intraoperative imaging system 
in real time. 
Materials and Methods 
Optical Property Measurements. We synthe-
sized a series of endocrine-specific near-infrared 
fluorophores (ESNF), and used them for lymph node 
targeting with a previously reported zwitterionic 
(ZW) heptamethine indocyanine molecule ZW800-3a 
[27]. To compare current commercially available NIR 
fluorophores, methylene blue (MB) purchased from 
Taylor Pharmaceuticals (Decatur, IL) and indocyanine 
green (ICG) purchased from Akorn Inc. (Decatur, IL) 
were also prepared. The optical properties of all 
agents were measured in fetal bovine serum (FBS) 
supplemented with 50 mM HEPES, pH 7.4. For 
quantum yield (QY) measurements of 700 nm fluor-
ophores (ESNF11, -14, -20), oxazine 725 in ethylene 
glycol (QY = 19%) was used as a calibration standard 
under conditions of matched absorbance at 655 nm 
[28, 29]. For the QY of 800 nm fluorophores 
(ZW800-3a), ICG in DMSO (QY = 13%) was used with 
a matched absorbance at 770 nm [30, 31]. For in vitro 
optical property measurements, fiberoptic HR2000 
absorbance (200-1100 nm) and USB2000FL fluores-
cence (350-1000 nm) spectrometers (Ocean Optics, 
Dunedin, FL) were employed. NIR excitation was 
provided by a 770 nm NIR laser diode light source 
(Electro Optical Components, Santa Rosa, CA) set to 8 
mW and coupled through a 300 µM core diameter, 
0.22 NA fiber (Fiberguide Industries, Stirling, NJ). In 
silico calculations of the partition coefficient (log D) 
and surface molecular charge and hydrophobicity 
were calculated using MarvinSketch 5.2.1 (ChemAx-
on, Budapest, Hungary) by evaluating major micro-
species at pH 7.4. 
Animal Models. Animals were housed in an 
AAALAC-certified facility. Animal studies were per-
formed under the supervision of Beth Israel Deacon-
ess Medical Center’s Institutional Animal Care and 
Use Committee (IACUC) in accordance with ap-
proved institutional protocols #155-2008 and 
#046-2010. We anesthetized male 300 g Spra-
gue-Dawley (SD) rats (Taconic Farms, Germantown, 
NY) with 80 mg/kg ketamine and 8 mg/kg xylazine 
intraperitoneally (Webster Veterinary, Fort Devens, 
MA). Female Yorkshire pigs (E.M. Parsons and Sons, 
Hadley, MA) averaging 35.4 kg were induced with 4.4 
mg/kg intramuscular Telazol™ (Fort Dodge Labs, 
Fort Dodge, IA), intubated, and maintained with 2% 
isoflurane (Baxter Healthcare Corp., Deerfield, IL). 
Following anesthesia, a 14 G central venous catheter 
was inserted into the external jugular vein, and saline 
was administered as needed. Electrocardiogram, 
heart rate, pulse oximetry, and body temperature 
were monitored throughout surgery.  
NIR Fluorescence Imaging System. The du-
al-NIR channel FLARE imaging system has been de-
scribed in detail previously [20, 30, 32]. In this study, 
670 nm excitation and 760 nm excitation fluorescence 
rates used were 4.0 and 11.0 mW/cm2, respectively, 
with white light (400 to 650 nm) at 40,000 lx. Color 
image and 2 independent channels (700 nm and 800 
nm) of NIR fluorescence images were acquired sim-
ultaneously with custom software at rates up to 15 Hz 
over a 15 cm diameter field of view (FOV). A custom 
filter set (Chroma Technology Corporation, Brattle-
boro, VT) composed of a 750 ± 25 nm excitation filter, 
a 785 nm dichroic mirror, and an 810 ± 20 nm emission 
filter were used to detect ZW800-3a and ICG. For 
ESNF detection, we used 650 ± 22 nm and 710 ± 25 nm 
excitation and emission filters, respectively. In the 
color-NIR merged images, 700 nm NIR fluorescence 
and 800 nm fluorescence were pseudo-colored bright 
red and lime green, respectively. The imaging system 
was positioned at a distance of 18 inches from the 
surgical field. 
NIR Fluorescence Microscopy. NIR fluores-
cence microscopy was performed on a 4-filter set Ni-
kon Eclipse TE300 epifluorescence microscope as 
previously described [33, 34]. The microscope was 
equipped with a 100 W mercury light source, 
NIR-compatible optics, and a NIR-compatible 10X 
Plan Fluor objective lens and a 100X Plan Apo oil 
immersion objective lens (Nikon, Melville, NY). Im-
ages were acquired on an Orca-AG (Hamamatsu, 
Bridgewater, NJ). Image acquisition and analysis was 
performed using IPLab software (Scanalytics, Fairfax, 
VA). The same NIR filter sets used for intraoperative 
FLARE imaging were used for microscopic imaging.  
NIR Imaging of Lymph Nodes in Rats and Pigs. 
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As Josephson et al. reported [26], intravenous injec-
tion rather than local injection should be used for PLN 
mapping to ensure labeling of all LNs. For PLN map-
ping using 700 nm NIR fluorophores, 50 nmol of MB 
or ESNF fluorophores were injected intravenously in 
rats. Injections of 20 nmol of ICG and ZW800-3a were 
used for 800 nm NIR imaging (n = 3 animals for each 
fluorophore). Four hours after injection, neck, axillary, 
inguinal, iliac, and mediastinal LNs were imaged. As 
a control, 3 rats were injected with 0.5 mL of saline 
and imaged as above. NIR fluorophores showing sig-
nificantly higher SBR (SBR ≥ 1.3) than the control (SBR 
≈ 1) were employed for further study. To examine the 
relationship between SBR of the LNs and observation 
timing, we observed 7 different time points (1, 2, 4, 8, 
12, 16, and 24 h) post-injection for each fluorophore (n 
= 3 animals for each). 
The same series of fluorophores were also used 
in a large animal study. The doses of contrast agents 
used for the large animals were as follows: 1.4 µmol 
for ESNF series and 640 nmol for ZW800-3a. First, the 
major LNs such as inguinal, gastric, mesenteric, and 
mediastinal LNs were observed 4 h post-injection (n = 
3 animals for each fluorophore). Second, the NIR 
fluorophore showing significantly higher fluorescence 
intensity (FI) was selected and injected into n = 3 pigs. 
LNs, muscle, liver, and kidney were observed at the 
indicated time (10 min, 30 min, 1 h, 2 h, 3 h, and 4 h). 
Finally, 3 pigs were used for dual-channel imaging of 
SLN and PLN mapping using ESNF and ZW800-3a 
simultaneously. Intravenously injected ZW800-3a 
(640 nmol in 0.5 mL saline) was used for PLN map-
ping, and 5 nmol ESNF injected locally into the uter-
ine cervix was used to visualize the SLN. The local 
injection procedure was the same method used in a 
recent clinical study by our group [24]. 
Quantitation and Statistical Analysis. The FI of 
a region of interest (ROI) over the LN, rectus abdom-
inis muscles, liver, and kidney were quantified using 
custom FLARE software. The performance metric for 
this study was the signal-to-background ratio (SBR). 
SBR = FI of ROI / background (BG) intensity. The 
rectus abdominis muscles, liver, and kidney were 
used as BG compared to the signal in LNs to yield SBR 
(LN/Mu), SBR (LN/Li), and SBR (LN/Ki). Results 
were presented as mean ± SEM. A one-way ANOVA 
followed by Tukey’s multiple comparisons post-test 
were used to assess the statistical differences between 
multiple groups. A P value ≤ 0.05 was considered 
significant. 
Results 
Optical Properties of NIR Fluorophores. The 
chemical structure, absorbance, and fluorescence 
curves for the ESNF series and ZW800-3a are shown 
in Figure 1. Detailed optical properties in 100% serum, 
pH 7.4 are shown in Table 1. All ESNF fluorophores 
have a 2-fold higher extinction coefficient and greater 
than 4-fold higher QY compared to the clinically 
available 700 nm fluorophore MB. The optical prop-
erties of ZW800-3a also appear to be higher (4-fold 
brighter) than the clinically available 800 nm fluoro-
phore ICG. ESNFs and ZW800-3a also have ideal 
separation in absorbance and fluorescence spectra, 
which permits simultaneous dual-channel NIR fluo-
rescence imaging. To summarize, ESNFs and MB ex-
hibited fluorescence properties compatible with NIR 
fluorescence channel #1 (700 nm) of the FLARE im-
aging system and NIR fluorescence microscope while 
ICG and ZW800-3a exhibited fluorescence properties 
compatible with NIR fluorescence channel #2 (800 
nm). 
 
Figure 1. Chemical Structures and Optical Properties of Lymph Node Contrast Agents: Shown are chemical structures (top) and optical properties (bottom) of 700 
nm (left) and 800 nm (right) lymph node contrast agents. FL, fluorescence; MW, molecular weight. 
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Table 1. Optical properties of NIR fluorophores in 100% FBS supplemented with 50 mM HEPES, pH 7.4. 
Property ESNF11 ESNF14 ESNF20 MB ZW800-3a ICG 
Extinction Coefficient (ε, M-1cm-1) 147,000 183,000 179,000 71,200 309,000 121,000 
Absorbance Maximum (nm) 656 696 692 665 774 807 
Emission Maximum (nm) 675 718 712 688 789 822 
Quantum Yield (ϕ, %) 45.3 21.5 15.8 3.8 16.1 9.3 
Molecular Brightness (ε × ϕ, M-1cm-1) 66,591 39,345 28,282 2,706 49,749 11,253 
 
 
Figure 2. Pan Lymph Node Imaging in Rats: 50 nmol ESNF14 (A) or 20 nmol ZW800-3a (B) was injected intravenously into SD rats 4 h prior to imaging. In the 
merged image, pseudo-colored red and green were used for 700 nm and 800 nm channels, respectively. LNs are identified with arrowheads. (C) SBR, expressed as 
the LN to muscle (Mu) ratio (mean ± SEM) for each agent in all major LN basins 4 h post- injection of 50 nmol ESNF series and MB, or 20 nmol ZW800-3a and ICG. 
Controls were injected with saline alone. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison post-test (*P < 0.05, **P 
< 0.01, ***P < 0.001). (D) Kinetics of pan lymph node NIR fluorescence. SBR, expressed as the LN to muscle (Mu) ratio (mean ± SEM) for each agent over time. (E) 
Biodistribution of intravenously injected NIR fluorophores 4 h post-injection. Data are from N = 3 rats per condition. Ad, white adipose; Bl, bladder; Du, duodenum; 
He, heart; In, intestine; Ki, kidney; Li, liver; Lu, lung; LN, lymph node. Scale bars = 1 cm. 
 
PLN Mapping in Rats. As shown in Figure 2A, 
ESNF14 accumulated significantly in LNs after a sin-
gle intravenous injection. However, nonspecific up-
take in muscle, adipose, liver, lung, and intestine in-
terfered with clear visualization of PLNs and re-
mained longer than 4 h post- injection. On the other 
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hand, intravenously injected ZW800-3a visualized 
PLNs with minimum nonspecific tissue uptake, which 
yielded more than 2-fold higher SBR (LN/Mu) com-
pared to ESNFs. By comparison, there was no signif-
icant difference in SBR between MB and saline con-
trols 4 h post-intravenous injection (Figure 2C), except 
for mesenteric LNs, which reabsorb MB from the GI 
tract after its excretion into bile [20]. In most cases, the 
SBR (LN/Mu) peaked between 4 h and 8 h over the 
course of 24 hours. Nonspecific background de-
creased significantly by 24 h post-injection; however, 
the signal at the target LNs also diminished rapidly by 
8 h post-injection. There was no significant difference 
between the SBR (LN/Mu) at 4 h and later time points 
up to 24 h (Figure 2D). Biodistribution of each com-
pound 4 h post-intravenous injection reveals slow 
elimination of ESNFs and ZW800-3a compared to MB 
and ICG.  
PLN Mapping in Pigs. Based on the small ani-
mal data, we performed PLN imaging in pigs (3 ani-
mals per fluorophore) at 4 h post-intravenous injec-
tion of each fluorophore. As shown in Figures 3A and 
B, ZW800-3a showed significantly higher SBR 
(LN/Mu) than all of the other fluorophores, which is 
consistent with the small animal data. ZW800-3a was 
then injected into 3 pigs and signals compared be-
tween PLNs and the varying background tissues 
(muscle, liver, and kidney) over 4 h. During the dis-
tribution phase, namely T = 0-1 h, SBR LN/Li and 
SBR LN/Ki were close to the baseline of 1.0. SBR then 
gradually increased over 4 h with peak SBR measured 
at 4 h post-intravenous injection (Figure 3C).  
 
Figure 3. Pan Lymph Node Imaging in Pigs: (A) Inguinal LNs (top), gastric LNs (2nd row), mesenteric LNs (3rd row) and mediastinal LNs (bottom) after intravenous 
injection of 640 nmol ZW800-3a into 35 kg Yorkshire pigs 4 h prior to imaging. Shown are representative images from N = 3 pigs, and pseudo-colored green was used 
for merged image. LNs are identified with arrowheads. Es, esophagus; Je, jejunum; Lu, lung; LN, lymph node; Pa, pancreas; St, stomach. Scale bars = 1 cm. (B) SBR, 
expressed as the LN to muscle (Mu) ratio (mean ± SEM) for each agent in all major LN basins 4 h after intravenous injection of 1.4 µmol ESNF series or 640 nmol 
ZW800-3a. Data are from N = 3 pigs per condition. Statistical analysis of ZW800-3a vs. each ESNF dye was performed using one-way ANOVA followed by Tukey’s 
multiple comparison post-test (*P < 0.05, **P < 0.01, ***P < 0.001). (C) Kinetics of pan lymph node NIR fluorescence. SBR, expressed as the LN to muscle (black 
squares), liver (white diamonds), or kidney (white circles) ratio (mean ± SEM) for each agent over time. N = 3 pigs per data point. 
 Theranostics 2014, Vol. 4, Issue 7 
 
http://www.thno.org 
698 
Simultaneous Dual-Channel Imaging of PLN 
and SLN Mapping in Pigs. Because completion 
lymphadenectomy is required in a large fraction of 
SLN biopsies, we attempted to visualize both SLN 
and PLNs simultaneously by exploiting the dual-NIR 
channel capability of the FLARE imaging system. In-
travenously injected ZW800-3a was selected for 800 
nm channel imaging because low nonspecific back-
ground is required for PLN mapping, while locally 
injected ESNF14 was used for 700 nm channel imag-
ing of the SLN. Four hours after intravenous injection 
of 640 nmol ZW800-3a, 5 nmol of ESNF14 was injected 
transvaginally and submucosally into the uterine cer-
vix (N = 3). Immediately after injection of ESNF14, the 
SLN (in this case the common iliac LN) was visualized 
on FLARE channel #1. Afterwards, both PLNs 
(FLARE channel #2) and the SLN could be imaged 
simultaneously (Figure 4A).  
For histological evaluation, we removed a con-
trol LN from the pelvic area before injection of any 
fluorophore. After injection of both ZW800-3a and 
ESNF14, we removed a pelvic LN showing signal 
from only ZW800-3a (i.e., PLN) and the SLN that dis-
played both ZW800-3a and ESNF14 fluorescence. 
Expected microscopic LN substructure [35] was con-
firmed by H&E staining, with each NIR fluorophore 
displaying a distinct LN uptake pattern. Control LNs 
were negative for NIR fluorescence (Figure 4B, top). 
For intravenously injected ZW800-3a, the cortex and 
supplying vasculature of the LN was bright (Figure 
4B, middle). For ESNF14, the subcapsular sinus 
showed the brightest signal (Figure 4B, bottom), con-
sistent with afferent lymphatic flow from the site of 
injection. 
 
 
 
Figure 4. Simultaneous Pan and Sentinel Lymph Node Mapping in Pig and Histological Analysis: (A) Sentinel lymph node mapping using 5 nmol of the 700 nm NIR 
fluorophore ESNF14 injected into the uterine cervix 5 min prior to imaging and pan lymph node mapping of the pelvic LNs using 640 nmol ZW800-3a injected 
intravenously 4 h prior to imaging in a 35 kg Yorkshire pig. Images are representative of N = 3 pigs, and pseudo-colored red and green were used in merged image 
for 700 nm and 800 nm channels, respectively. LNs are identified with arrowheads. The SLN is identified with a red broken circle. Bl, bladder; Ov, ovary; Re, rectum. 
Dashed circle = SLN; arrowheads = pelvic LNs. Scale bar = 1 cm. (B) Histological analysis NIR fluorescence within pelvic LNs. Control LNs (top row) are from 
uninjected pigs. Pan lymph node (PLN; middle row) and sentinel lymph node (SLN; bottom row) are from Figure 4A. For each are shown hematoxylin and eosin (H&E) 
brightfield images (left column), consecutive histological sections viewed under 700 nm (2nd column) and 800 nm (3rd column) NIR fluorescence, and a pseudocolored 
merge of the three (right column). NIR fluorescence images have identical exposure times and normalizations. Scale bars = 100 µm. LF, lymphoid follicle; S, sub-
capsular sinus. 
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Discussion 
SLN mapping is the standard of care for breast 
cancer and melanoma, and is also being investigated 
for the staging of many other solid tumors. In ap-
proximately 30% to 40% of breast cancer cases [10, 11] 
and 15% to 20% of melanoma cases [12, 13], though, a 
positive SLN is found and a completion lymphade-
nectomy is required. Additionally, the proper staging 
and treatment of cervical cancer requires an extensive 
LN dissection in the pelvis and around the descend-
ing aorta. Pelvic anatomy is very complicated, and 
there are currently no methods available to help sur-
geons to locate all LNs within a basin. As a result, 
dissection of LNs is often associated with intraopera-
tive morbidity, such as hemorrhage, nerve damage, 
and long-term morbidity, such as serocele formation 
and lymphedema [36]. Ideally, a PLN agent could be 
injected intravenously at a relatively low dose prior to 
surgery, home specifically to all lymph nodes in the 
body, and provide real-time, high sensitivity image 
guidance to the surgeon during lymphadenectomy. 
Currently available clinical NIR fluorophores, MB and 
ICG, cannot visualize PLNs after intravenous injec-
tion. Josephson et al. used Cy5.5-PGC for NIR imag-
ing of PLN mapping [26]; however, the fluorophore 
resulted in high nonspecific background uptake in 
most tissues and organs, especially the liver. A clini-
cally useful agent needs to exhibit low nonspecific 
uptake in major organs and tissues as well as high 
signal in LNs [37].  
An in vivo pilot study demonstrated that both 
ESNFs and ZW800-3a are viable SLN tracers, with 
both visualizing the SLN immediately (within 1 min), 
and with high SBR (> 5.0) and long retention time (> 1 
h) after local injection (data not shown). Based on this 
result, we systematically investigated the possibility 
of using these agents for mapping all LNs in the body 
after single intravenous injection. Although all fluor-
ophores displayed reasonably good signal in PLNs, 
the 700 nm ESNF series exhibited high nonspecific 
background uptake in muscle, adipose, kidneys, and 
liver that limited their utility for PLN mapping. On 
the other hand, 800 nm ZW800-3a provided high SBR 
in PLNs in both small and large animal models as a 
result of low nonspecific background uptake, higher 
excitation and emission wavelength (i.e., lower tissue 
attenuation), lower autofluorescence, and optimal 
optical properties (Table 1).  
It should be noted that the proper statistical as-
sessment of SLN biopsy, which includes sensitivity, 
specificity, positive predictive value, negative predic-
tive value, and accuracy, is dependent on finding all 
LNs within a basin. The technology we describe 
should aid in this endeavor, and might someday 
permit improved quantitative evaluation of SLN bi-
opsy for cancers other than breast cancer and mela-
noma.  
Although ZW800-3a performs reasonably well as 
a PLN agent, and has excellent optical properties, its 
specificity requires additional optimization. The 
mechanism of uptake in lymph nodes is presently not 
known, although micro-precipitation is unlikely be-
cause of the absence of signal in lung and spleen. The 
combination of logD, surface charge, and chemical 
structure appears to have specificity for LN uptake 
and retention, with our histological data suggesting 
that the fluorophore is being delivered via the sys-
temic vasculature. Future studies should be directed 
at defining the mechanism of uptake and improving 
specificity, while maintaining current optical proper-
ties. cGMP-compatible chemical syntheses will also 
need to be developed to enable first-in-human clinical 
trials.  
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